Transurethral injection of autologous muscle precursor cells for treatment of female stress urinary incontinence: a prospective phase I clinical trial

Introduction and hypothesis The purpose was to investigate the safety and feasibility of transurethral injections of autologous muscle precursor cells (MPCs) into the external urinary sphincter (EUS) to treat stress urinary incontinence (SUI) in female patients.

Methods Prospective and randomised phase I clinical trial.

Standardised 1-h pad test, International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF), urodynamic study, and MRI of the pelvis were performed at baseline and 6 months after treatment.

MPCs gained through open muscle biopsy were transported to a GMP facility for processing and cell expansion.

The final product was injected into the EUS via a transurethral ultrasound-guided route.

Primary outcomes were defined as any adverse events (AEs) during follow-up.

Secondary outcomes were functional, questionnaire, and radiological results.

Results Ten female patients with SUI grades I–II were included in the study and 9 received treatment.

Out of 8 AEs, 3 (37.5%) were potentially related to treatment and treated conservatively: 1 urinary tract infection healed with antibiotics treatment, 1 dysuria and 1 discomfort at biopsy site.

Functional urethral length under stress was 25 mm at baseline compared with 30 mm at 6 months’ follow-up ( p =0.009).

ICIQ-UI-SF scores improved from 7 points at baseline to 4 points at follow-up ( p =0.035).

MRI of the pelvis revealed no evidence of tumour or necrosis, whereas the diameter of the EUS muscle increased from 1.8 mm at baseline to 1.9 mm at follow-up ( p =0.009).

Conclusion Transurethral injections of autologous MPCs into the EUS for treatment of SUI in female patients can be regarded as safe and feasible.

Only a minimal number of expected and easily treatable AEs were documented.